Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Ann Clin Transl Neurol ; 7(9): 1608-1619, 2020 09.
Article in English | MEDLINE | ID: mdl-32794343

ABSTRACT

BACKGROUND: Recent findings suggest that individuals with Huntington's disease (HD) have an impaired capacity to execute cognitive and motor tasks simultaneously, or dual task, which gradually worsens as the disease advances. The onset and neuropathological changes mediating impairments in dual tasking in individuals with HD are unclear. The reliability of dual tasking assessments for individuals with HD is also unclear. OBJECTIVES: To evaluate differences in dual tasking performance between individuals with HD (presymptomatic and prodromal) and matched controls, to investigate associations between striatal volume and dual tasking performance, and to determine the reliability of dual tasking assessments. METHODS: Twenty individuals with HD (10 presymptomatic and 10 prodromal) and 20 healthy controls were recruited for the study. Individuals undertook four single and dual task assessments, comprising motor (postural stability or force steadiness) and cognitive (simple or complex mental arithmetic) components, with single and dual tasks performed three times each. Participants also undertook a magnetic resonance imaging assessment. RESULTS: Compared to healthy controls, individuals with presymptomatic and prodromal HD displayed significant deficits in dual tasking, particularly cognitive task performance when concurrently undertaking motor tasks (P < 0.05). The observed deficits in dual tasking were associated with reduced volume in caudate and putamen structures (P < 0.05),however, not with clinical measures of disease burden. An analysis of the reliability of dual tasking assessments revealed moderate to high test-retest reliability [ICC: 0.61-0.99] for individuals with presymptomatic and prodromal HD and healthy controls. CONCLUSIONS: Individuals with presymptomatic and prodromal HD have significant deficits in dual tasking that are associated with striatal degeneration. Findings also indicate that dual tasking assessments are reliable in individuals presymptomatic and prodromal HD and healthy controls.


Subject(s)
Cognitive Dysfunction/physiopathology , Executive Function/physiology , Huntington Disease/pathology , Huntington Disease/physiopathology , Neostriatum/pathology , Postural Balance/physiology , Psychomotor Performance/physiology , Adult , Humans , Huntington Disease/complications , Magnetic Resonance Imaging , Male , Middle Aged , Neostriatum/diagnostic imaging , Prodromal Symptoms
2.
J Neurol Sci ; 416: 117022, 2020 09 15.
Article in English | MEDLINE | ID: mdl-32688143

ABSTRACT

BACKGROUND: Huntington's disease (HD) is a chronic, progressive neurodegenerative condition for which there are currently no proven disease-modifying therapies. Lifestyle factors have been shown to impact on the age of disease onset and progression of disease features. We therefore investigated the effects of a nine-month multidisciplinary rehabilitation intervention on neuroimaging, biological and clinical disease outcomes in individuals with premanifest HD. METHODS: 31 individuals with premanifest HD participated in the study. Eighteen participants underwent a nine-month multidisciplinary rehabilitation intervention comprising aerobic and resistance exercise, computerised cognitive training, dual-task training and sleep hygiene and nutritional guidance. The remaining 13 participants were allocated to a standard care control group. Neuroimaging, biological, cognitive, motor and cardiorespiratory fitness data was collected. RESULTS: Participants displayed good adherence (87%) and compliance (85%) to the intervention. Maintenance of the shape of the right putamen was observed in the intervention group when compared to the control group. The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group. Performance on the mini-social cognition and emotional assessment (mini-SEA) was maintained in the intervention group, but decreased in the control group. No changes were observed in serum neurofilament light protein levels, postural stability outcomes or cardiorespiratory fitness. CONCLUSION: This study adds to the accumulating body of literature to suggest that multidisciplinary rehabilitation is of clinical benefit for individuals with HD. Large randomised controlled trials are necessary to determine the extent to which benefits occur across the spectrum of the disease.


Subject(s)
Cognition Disorders , Huntington Disease , Cognition , Humans , Huntington Disease/complications , Huntington Disease/diagnostic imaging , Huntington Disease/therapy , Neuroimaging
4.
J Neurol Sci ; 408: 116522, 2020 Jan 15.
Article in English | MEDLINE | ID: mdl-31665619

ABSTRACT

BACKGROUND: Hypothalamic pathology is a well-documented feature of Huntington's disease (HD) and is believed to contribute to circadian rhythm and habitual sleep disturbances. Currently, no therapies exist to combat hypothalamic changes, nor circadian rhythm and habitual sleep disturbances in HD. OBJECTIVE: To evaluate the effects of multidisciplinary rehabilitation on hypothalamic volume, brain-derived neurotrophic factor (BDNF), circadian rhythm and habitual sleep in individuals with preclinical HD. METHODS: Eighteen individuals with HD (ten premanifest and eight prodromal) undertook a nine-month multidisciplinary rehabilitation intervention (intervention group), which included exercise, cognitive and dual task training and social events, and were compared to a community sample of eleven individuals with premanifest HD receiving no intervention (control group). Hypothalamic volume, serum BDNF, salivary cortisol and melatonin concentrations, subjective sleep quality, daytime somnolence, habitual sleep-wake patterns, stress and anxiety and depression symptomatology were evaluated. RESULTS: Hypothalamus grey matter volume loss was significantly attenuated in the intervention group compared to the control group after controlling for age, gender, Unified Huntington's Disease Rating Scale-Total Motor Score and number of cytosine-adenine-guanine repeats. Serum BDNF levels were maintained in the intervention group, but decreased in the control group following the study period. Both groups exhibited decreases in cortisol and melatonin concentrations. No changes were observed in sleep or mood outcomes. CONCLUSIONS: This exploratory study provides evidence that multidisciplinary rehabilitation can reduce hypothalamic volume loss and maintain peripheral BDNF levels in individuals with preclinical HD but may not impact on circadian rhythm. Larger, randomised controlled trials are required to confirm these findings.


Subject(s)
Brain-Derived Neurotrophic Factor , Gray Matter/diagnostic imaging , Huntington Disease/diagnostic imaging , Huntington Disease/rehabilitation , Hypothalamus/diagnostic imaging , Prodromal Symptoms , Adult , Brain-Derived Neurotrophic Factor/blood , Circadian Rhythm/physiology , Female , Follow-Up Studies , Gray Matter/physiology , Humans , Huntington Disease/blood , Hypothalamus/physiology , Male , Middle Aged , Organ Size , Pilot Projects , Sleep/physiology , Time Factors
5.
Acta Neurol Scand ; 138(6): 500-507, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30058184

ABSTRACT

OBJECTIVE: The primary objective of this trial was to evaluate the effects of outpatient multidisciplinary therapy, compared to usual care, on measures of physical function and muscle strength in patients with manifest Huntington's disease (HD). METHODS: Twenty-two patients with clinically verified HD were randomized to receive 36 weeks of outpatient multidisciplinary therapy or usual care. Outpatient multidisciplinary therapy comprised 9 months of supervised exercise, cognitive therapy and self-directed home-based exercise. Usual care consisted of standard medical care. Patients were assessed at 0 and 36 weeks by blinded assessors. The primary outcome was changed in mobility as measured by the 10-m Timed Walk Test. Secondary outcome measures included changes in manual dexterity (Timed Nut and Bolt Test), balance (Berg Balance Scale), cardiorespiratory endurance (6-Minute Walk Test) and upper and lower extremity muscle strength (isokinetic and isometric muscle strength and 10 Repetition Sit-to-Stand Tests). RESULTS: Patients receiving outpatient multidisciplinary therapy demonstrated significantly enhanced manual dexterity (P < 0.05) and lower extremity muscle strength (P < 0.05) than patients receiving usual care. No significant differences in mobility, balance, cardiorespiratory endurance and upper extremity strength outcomes were observed between groups after the intervention period. There were no adverse events associated with multidisciplinary therapy. CONCLUSION: Our findings suggest that outpatient multidisciplinary therapy has positive effects on manual dexterity and muscle strength, but no meaningful effects on mobility, balance, cardiorespiratory endurance and upper extremity muscle strength in patients with HD. Larger randomized controlled trials are needed to confirm these preliminary findings.


Subject(s)
Cognitive Behavioral Therapy/methods , Exercise Therapy/methods , Huntington Disease/rehabilitation , Female , Humans , Male , Middle Aged
6.
J Pediatr Oncol Nurs ; 34(6): 439-445, 2017.
Article in English | MEDLINE | ID: mdl-28699409

ABSTRACT

Enteral supplementation for nutritional support in pediatric oncology patients remains nonstandardized across institutions and between providers. Pediatric oncology patients frequently fail to meet their growth curve percentiles, lose weight, and/or are malnourished due to both the oncologic process as well as side effects from chemotherapy and radiation treatments. Methods of increasing weight include enteral feeding (nasogastric, nasoduodenal/jejunal, or gastrostomy), parenteral intravenous feeding, and oral supplementation. Indications for feeding and feeding protocols are highly variable, in part due to parental and familial choices, and in part due to the lack of guidelines available for providers. This article provides a comprehensive literature review of 8 published studies regarding the effectiveness and safety of enteral feeding in maintaining or increasing weight in pediatric oncology patients to help inform practice. The review concludes that enteral feeding in pediatric oncology patients is an effective and safe method to affect weight positively. However, further research is needed for developing treatment guidelines, including establishing a timeline for initiation of feeding, and determining which patients are most likely to benefit from enteral feeding.


Subject(s)
Enteral Nutrition/standards , Gastrostomy/standards , Intubation, Gastrointestinal/standards , Oncology Nursing/standards , Parenteral Nutrition/standards , Pediatric Nursing/standards , Practice Guidelines as Topic , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male
7.
Int J Burns Trauma ; 7(7): 124-141, 2017.
Article in English | MEDLINE | ID: mdl-29348976

ABSTRACT

BACKGROUND: Ultrasound elastography is an imaging technology which can objectively and non-invasively assess tissue stiffness. It is emerging as a useful marker for disease diagnosis, progression and treatment efficacy. OBJECTIVE: To examine current, published research evaluating the use of ultrasound elastography for the measurement of cutaneous or subcutaneous stiffness and to determine the level of validity and reliability, recommended methodologies and limitations. METHODS: MEDLINE, Web of science and Scopus were systematically searched in August 2016 to identify original articles evaluating the use of ultrasound elastography to assess cutaneous stiffness. Relevant studies were then quality evaluated using the Quality Assessment of Diagnostic Accuracy Studies v 2 (QUADAS-2) tool and the Quality Appraisal of Reliability Studies (QAREL). RESULTS: From a total of 688 articles, 14 met the inclusion criteria for full review. Within the 14 studies, elastography was used to evaluate tumors, systemic sclerosis, lymphedema, abscess, and post-radiation neck fibrosis. Only three robust studies demonstrated good interrater reliability, whereas all validity studies had low sample sizes and demonstrated risks of bias. CONCLUSION: Robust evidence supporting the use of ultrasound elastography as a diagnostic tool in cutaneous conditions is low, however, initial indicators support further research to establish the utility of ultrasound elastography in dermatology.

8.
World Neurosurg ; 98: 879.e9-879.e11, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27876658

ABSTRACT

BACKGROUND: The carotid web is an intraluminal shelf-like projection arising from the posterior wall of the carotid bifurcation and an uncommon etiology of ischemic strokes. We describe the feasibility of endovascular stent placement to treat this condition. CASE REPORT: A 47-year-old woman presented with a sudden occlusion of the right middle cerebral artery. Computed tomography angiography and digital subtraction angiography showed a carotid web in the ipsilateral carotid bifurcation. Treatment included mechanical thrombectomy for the middle cerebral artery occlusion and carotid stent placement to prevent further ischemic episodes from the carotid web. At the 6-month follow-up, good apposition of the stent against the artery wall was noted, and the patient was free of neurologic symptoms. CONCLUSIONS: Carotid artery stent placement is a feasible option in the management of carotid webs.


Subject(s)
Infarction, Middle Cerebral Artery/surgery , Stents , Thrombectomy/instrumentation , Thrombectomy/methods , Angiography, Digital Subtraction , Cerebral Angiography , Female , Follow-Up Studies , Humans , Infarction, Middle Cerebral Artery/diagnostic imaging , Middle Aged , Tomography, X-Ray Computed
9.
Neurosci Biobehav Rev ; 71: 444-454, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27637496

ABSTRACT

Huntington's disease (HD) is a fatal neurodegenerative disease caused by an extended polyglutamine tract in the huntingtin protein. Circadian, sleep and hypothalamic-pituitary-adrenal (HPA) axis disturbances are observed in HD as early as 15 years before clinical disease onset. Disturbances in these key processes result in increased cortisol and altered melatonin release which may negatively impact on brain-derived neurotrophic factor (BDNF) expression and contribute to documented neuropathological and clinical disease features. This review describes the normal interactions between neurotrophic factors, the HPA-axis and circadian rhythm, as indicated by levels of BDNF, cortisol and melatonin, and the alterations in these intricately balanced networks in HD. We also discuss the implications of these alterations on the neurobiology of HD and the potential to result in hypothalamic, circadian, and sleep pathologies. Measurable alterations in these pathways provide targets that, if treated early, may reduce degeneration of brain structures. We therefore focus here on the means by which multidisciplinary therapy could be utilised as a non-pharmaceutical approach to restore the balance of these pathways.


Subject(s)
Huntington Disease , Brain-Derived Neurotrophic Factor , Humans , Hypothalamo-Hypophyseal System , Hypothalamus , Pituitary-Adrenal System
10.
Brain Behav ; 5(2): e00312, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25642394

ABSTRACT

BACKGROUND: There is a wealth of evidence detailing gray matter degeneration and loss of cognitive function over time in individuals with Huntington's disease (HD). Efforts to attenuate disease-related brain and cognitive changes have been unsuccessful to date. Multidisciplinary rehabilitation, comprising motor and cognitive intervention, has been shown to positively impact on functional capacity, depression, quality of life and some aspects of cognition in individuals with HD. This exploratory study aimed to evaluate, for the first time, whether multidisciplinary rehabilitation can slow further deterioration of disease-related brain changes and related cognitive deficits in individuals with manifest HD. METHODS: Fifteen participants who manifest HD undertook a multidisciplinary rehabilitation intervention spanning 9 months. The intervention consisted of once-weekly supervised clinical exercise, thrice-weekly self-directed home based exercise and fortnightly occupational therapy. Participants were assessed using MR imaging and validated cognitive measures at baseline and after 9 months. RESULTS: Participants displayed significantly increased gray matter volume in the right caudate and bilaterally in the dorsolateral prefrontal cortex after 9 months of multidisciplinary rehabilitation. Volumetric increases in gray matter were accompanied by significant improvements in verbal learning and memory (Hopkins Verbal Learning-Test). A significant association was found between gray matter volume increases in the dorsolateral prefrontal cortex and performance on verbal learning and memory. CONCLUSIONS: This study provides preliminary evidence that multidisciplinary rehabilitation positively impacts on gray matter changes and cognitive functions relating to verbal learning and memory in individuals with manifest HD. Larger controlled trials are required to confirm these preliminary findings.


Subject(s)
Brain/pathology , Cognition/physiology , Huntington Disease/pathology , Huntington Disease/rehabilitation , Aged , Brain/physiopathology , Brain Mapping , Disease Progression , Female , Follow-Up Studies , Humans , Huntington Disease/physiopathology , Huntington Disease/psychology , Life Style , Magnetic Resonance Imaging , Male , Middle Aged , Pilot Projects
11.
Clin. transl. oncol. (Print) ; 13(9): 686-691, sept. 2011. tab
Article in English | IBECS | ID: ibc-125874

ABSTRACT

INTRODUCTION: The objective was to evaluate a dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant treatment for patients with locally advanced breast cancer. PATIENTS AND METHODS: Ninety-nine patients were included and received 100 mg/m(2) of docetaxel every two weeks for four cycles followed by 60 mg/m(2) of doxorubicin and 600 mg/m(2) of cyclophosphamide every two weeks for four cycles. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was administered systematically to all patients. RESULTS: Efficacy and toxicity analyses were carried out on an intention-to-treat basis. After treatment, complete pathological response in the breast and lymph nodes was confirmed in 15 patients (15%, 95% confidence interval [CI]: 8.4-22.9). Clinical response rate was 74% (95% CI: 65-82), of which 19% were complete responses. Breast-conserving surgery could be performed in 41% of patients. The dose-dense schedule was generally well tolerated. The most important grade 3/4 toxicities per patient were cutaneous toxicity (12.1%) and hepatic dysfunction (9.1%) during docetaxel administration, and neutropenia (28.1%) and leucopenia (8.3%) with AC. CONCLUSION: A dose-dense schedule of docetaxel followed by AC as neoadjuvant treatment is an effective and safe treatment for locally advanced breast cancer. Primary prophylaxis with G-CSF, and possibly the change in the sequence of drug administration, appears to play a major role in avoiding the excessive toxicity of dose-dense schedule (AU)


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Taxoids/administration & dosage , Cyclophosphamide/adverse effects , Dose-Response Relationship, Drug , Doxorubicin/adverse effects , Neoadjuvant Therapy/methods , Neoadjuvant Therapy , Neoadjuvant Therapy , Taxoids/adverse effects , Treatment Outcome , Drug Administration Schedule
12.
J Strength Cond Res ; 24(4): 978-84, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19996779

ABSTRACT

This study examined a modification of the Margaria-Kalamen test for football players. The football stair climb test (FST) protocol used in this study increased the vertical displacement (20 steps, 3.12 m) so that the mean best time for the test was 2.048 +/- 0.267 seconds. Fifty-eight Division I-A football players volunteered to participate (mean +/- SD age = 20.2 +/- 1.8 yr, height = 184.1 +/- 7.7 cm, weight = 102.5 +/- 19.4 kg). Subjects performed 25 trials with 30 to 40 seconds of rest between trials. Test-retest reliability was determined using 34 subjects by way of intraclass correlation coefficients with a value of 0.73 for peak power and SEM of 105.4 W, indicating an acceptable level of reliability. Subjects were divided into 3 groups by position: linemen (Line), skill, and linebackers (LB). Alpha level was p < 0.05. Peak power was 1674.5 +/- 300.8, 1712.6 +/- 251.5, and 1388.6 +/- 210.4 W for the LB, Line, and Skill groups, respectively. Groups were significantly different (p < 0.0001), with the LB and Line found to be more powerful than the Skill group. Peak power continued to increase throughout the 25 trials in the Skill and LB group but plateaued after approximately 17 trials in the Line group. It was concluded that the FST was a reliable test for measuring peak anaerobic power in collegiate football players, which, theoretically, should provide more accurate measures of peak power caused by increased vertical displacement and longer duration, resulting in a decreased influence of cheating strategies during test administration. To achieve maximal power in stair climbing tasks, coaches may need to incorporate a greater number of trials or a more intense warm-up than has been previously reported.


Subject(s)
Anaerobic Threshold/physiology , Exercise Test/methods , Football/physiology , Muscle Strength/physiology , Physical Exertion/physiology , Analysis of Variance , Anthropometry , Cohort Studies , Humans , Male , Physical Endurance/physiology , Physical Fitness/physiology , Reproducibility of Results , Sensitivity and Specificity , Young Adult
13.
Psychooncology ; 19(10): 1094-101, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20014184

ABSTRACT

OBJECTIVE: To describe spouses' reported cancer-related demands attributed to their wife's breast cancer, and to test the construct and predictive validity of a brief standardized measure of these demands. METHODS: Cross-sectional and longitudinal data were obtained from 151 spouses of women newly diagnosed with non-metastatic breast cancer. Descriptive statistics were computed to describe spouses' dominant cancer-related demands, and multivariate regression analyses tested the construct and predictive validity of the standardized measure. RESULTS: Five categories of spouses' cancer-related demands were identified, such as concerns about spouses' own functioning, wife's well-being and response to treatment, couples' sexual activities, the family's and children's well-being, and the spouses' role in supporting their wives. A 33-item short version of the standardized measure of cancer demands demonstrated construct and predictive validity that was comparable to a 123-item version of the same questionnaire. Greater numbers of illness demands occurred when spouses were more depressed and had less confidence in their ability to manage the impact of the cancer (F=18.08 (3,103), p<0.001). Predictive validity was established by the short form's ability to significantly predict the quality of marital communication and spouses' self-efficacy at a 2-month interval. CONCLUSION: The short version of the standardized measure of cancer-related demands shows promise for future application in clinic settings. Additional testing of the questionnaire is warranted. Spouses' breast cancer-related demands deserve attention by providers. In the absence of assisting them, spouses' illness pressures have deleterious consequences for the quality of marital communication and spouses' self-confidence.


Subject(s)
Breast Neoplasms/psychology , Depression , Spouses/psychology , Stress, Psychological , Surveys and Questionnaires , Adaptation, Psychological , Adult , Breast Neoplasms/diagnosis , Cross-Sectional Studies , Female , Humans , Interpersonal Relations , Longitudinal Studies , Male , Middle Aged , Personal Satisfaction , Psychiatric Status Rating Scales , Regression Analysis , Reproducibility of Results , Socioeconomic Factors
14.
Clin. transl. oncol. (Print) ; 10(11): 739-744, nov. 2008. tab
Article in English | IBECS | ID: ibc-123548

ABSTRACT

INTRODUCTION: To evaluate the efficacy and safety profile of the concomitant dose-dense administration of doxorubicin and docetaxel as primary chemotherapy for patients with large or locally advanced breast cancer. MATERIALS AND METHODS: Forty-seven patients were included and received 50 mg/m(2) of doxorubicin and 75 mg/m(2) of docetaxel every two weeks for four cycles. Primary prophylaxis with granulocyte colony stimulating factor was administered. RESULTS: Patients included had mainly stage III disease (66%). Efficacy and toxicity analyses were carried out on an intention-to-treat basis. After study treatment, the rate of clinical responses was 85% (95% CI: 75-95) with 6% judged as clinical complete responses. Surgery was performed on 94% patients for whom the breast was conserved in 27%. Only one patient obtained a pathological complete response (with no evidence of invasive or non-invasive tumour in the breast and the lymph nodes). In three additional patients, malignant cells were detected only in one lymph node. The single severe haematological toxicity was neutropenia, occurring in one patient (2%) and two cycles (1%), being grade 3 in one and grade 4 in the other. Severe non-haematological toxicities were grade 3, and the most common was asthenia (8% of patients), followed by cutaneous toxicity, arthromyalgia and stomatitis, which occurred in fewer than 4% of patients in each case. CONCLUSIONS: The concomitant dose-dense administration of doxorubicin and docetaxel as neoadjuvant chemotherapy with granulocyte colony stimulating factor support is a feasible and effective schedule with a safe toxicity profile for women with large or locally advanced breast cancer (AU)


No disponible


Subject(s)
Humans , Female , Middle Aged , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Carcinoma/drug therapy , Granulocyte Colony-Stimulating Factor/therapeutic use , Neoadjuvant Therapy , Doxorubicin/adverse effects , Antineoplastic Agents/adverse effects , Asthenia/chemically induced , Combined Modality Therapy , Drug Eruptions/etiology , Mastectomy , Neutropenia/chemically induced , Prospective Studies , Stomatitis/chemically induced , Taxoids/administration & dosage , Taxoids/adverse effects
15.
Can J Infect Dis Med Microbiol ; 18(2): 133-7, 2007 Mar.
Article in English | MEDLINE | ID: mdl-18923714

ABSTRACT

OBJECTIVE: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli are increasingly common in nosocomial and community settings. Furthermore, fluoroquinolone (FQ) and even multidrug resistance (MDR) appear to be associated with certain ESBL genotypes. The purpose of the present study was to determine which ESBL genotypes are associated with FQ and MDR in E coli urinary isolates in Manitoba. METHODS: The authors determined the antimicrobial susceptibility, genetic similarity and ESBL genotype of 27 FQ-resistant and seven FQ-susceptible, ESBL-producing urinary isolates submitted to the clinical microbiology laboratories of two teaching hospitals between October 2000 and April 2005. Susceptibilities to beta-lactams, FQs, trimethoprim-sulfamethoxazole (SXT), doxycycline (DOX), gentamicin (GM) and tigecycline were determined by microbroth dilution; pulsed-field gel electrophoresis (PFGE) was used to determine genetic relatedness, and ESBL genotype was determined by polymerase chain reaction and sequencing. RESULTS: Of 34 ESBL-producing organisms, 27 (79.4%) were found to be ciprofloxacin (CIP) resistant, 27 (79.4%) were SXT resistant, eight (23.5%) were GM resistant and 29 (85.3%) were DOX resistant. Twenty-three (67.6%) had MDR, with concomitant resistance to CIP and SXT; 16 had concomitant resistance to CIP, SXT and DOX; and seven (20.6%) had MDR, with concomitant resistance to CIP, SXT, DOX and GM. All isolates were susceptible to tigecycline. Of 27 FQ-resistant ESBL-producing organisms, seven (25.9%) were genotype CTX-M-14, 19 (70.4%) were genotype CTX-M-15 and one (3.7%) was genotype CTX-M-24. Among the seven FQ-susceptible strains, three (42.8%) expressed SHV-type enzymes, three (42.8%) expressed TEM-type enzymes and one (14.3%) expressed CTX-M-9. CTX-M-15 was the most common MDR-associated genotype. Of a total of 19 strains, 18 (94.7%) were resistant to FQs and SXT; 15 (78.9%) were resistant to FQs, SXT and DOX; and five (26.3%) were resistant to FQs, SXT, DOX and GM. PFGE analysis revealed genetic similarity within CTX-M-15-producing isolates only. CONCLUSION: CTX-M-15 in E coli is strongly associated with an MDR phenotype compared with other genotypes. CTX-M-14 is associated with FQ resistance only. PFGE suggests clonality of CTX-M-15-producing isolates within and among hospitals.

16.
J Am Coll Cardiol ; 47(7): 1350-5, 2006 Apr 04.
Article in English | MEDLINE | ID: mdl-16580520

ABSTRACT

OBJECTIVES: The purpose of this study was to examine the two-year clinical outcomes in patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study. BACKGROUND: The SIRIUS study was a double-blinded randomized study which demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS). METHODS: Patients with de novo native coronary artery lesions randomized to either SES (533 patients) or control BMS (525 patients) were followed for two years. RESULTS: Between one and two years, there were infrequent additional clinical events that were equally distributed between the sirolimus and control groups. After two years, target lesion revascularization was 5.8% and 21.3% in SES and control patients, respectively (p < 0.001), and major adverse cardiovascular events and target vessel failure rates were 10.1% versus 24.4% and 12.0% versus 26.7%, respectively (p < 0.0001 for both). There were no differences in death, myocardial infarction, and stent thrombosis between the two groups. CONCLUSIONS: Clinical outcomes two years after implantation of SES continue to demonstrate significant reduction in the need for repeat target lesion (and vessel) revascularization compared with BMS without evidence for either disproportionate late restenosis or late stent thrombosis.


Subject(s)
Coronary Disease/therapy , Sirolimus/administration & dosage , Stents , Coronary Angiography , Coronary Disease/diagnostic imaging , Double-Blind Method , Follow-Up Studies , Humans , Incidence , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Sirolimus/therapeutic use , Stents/adverse effects , Thrombosis/epidemiology , Thrombosis/etiology , Treatment Outcome
17.
Dev Growth Differ ; 47(9): 627-35, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16316407

ABSTRACT

The transcription factor encoded by PAX3 is among the first expressed in the embryo, with a key role in development of the melanocytic lineage. Re-expression of PAX3, consistently observed in cutaneous malignant melanoma (CMM) as compared to normal melanocytes, appears linked to progression of CMM. Previous research has identified PAX3d (encoded by exons 1-9) as the predominant isoform present in CMM, together the with an alternate isoform PAX3c (encoded by exons 1-8). We investigated the expression of Pax3c and Pax3d transcripts during mouse development. The reverse transcription-polymerase chain reaction and immunohistochemistry experiments presented here implicate these transcripts in melanoblast development and demonstrate significant spatial and temporal differences in their expression. Differences in expression were also noted during active hair regrowth in adult skin, which is accompanied by proliferation and migration of melanoblasts into the hair cortex to color new hair. Results indicate that the defined spatial and temporal expression of Pax3d may be linked to either melanoblast proliferation or migration during melanogenesis.


Subject(s)
Melanocytes/physiology , Melanoma/genetics , Paired Box Transcription Factors/genetics , Animals , Base Sequence , Brain/embryology , Brain/growth & development , Brain/physiology , Cell Movement/physiology , Cell Proliferation , Female , Gene Expression Regulation, Developmental , Hair Follicle/embryology , Hair Follicle/physiology , Hair Follicle/ultrastructure , Humans , Immunohistochemistry , Melanocytes/cytology , Melanocytes/ultrastructure , Melanoma/chemistry , Melanoma/metabolism , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Muscle, Skeletal/embryology , Muscle, Skeletal/growth & development , Muscle, Skeletal/physiology , PAX3 Transcription Factor , Paired Box Transcription Factors/metabolism , Pregnancy , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Transcription, Genetic
18.
Ann Oncol ; 13(11): 1756-62, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12419748

ABSTRACT

BACKGROUND: The objectives of this study were to evaluate the efficacy and toxicity of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur (UFT) in patients with advanced adenocarcinoma of the pancreas. PATIENTS AND METHODS: Forty-three chemotherapy-naïve patients with adenocarcinoma of the pancreas were included in this phase II study. All of whom had a Karnofsky performance status >or=50 and bi-dimensionally measurable disease (either advanced non-resectable or metastatic); median age 59 years (range 39-77); male:female ratio 29:14. Eight patients (19%) had locally advanced disease and 35 (81%) distant metastases. Treatment consisted of gemcitabine 1200 mg/m(2) given as a 120-min infusion weekly for 3 consecutive weeks, plus oral UFT 400 mg/m(2)/day (in 2-3 doses per day) on days 1-21, cycles were given every 28 days. Measurements of efficacy included response rate, clinical benefit response, time to disease progression and overall survival. RESULTS: A total of 192 cycles of chemotherapy were delivered with a median of four per patient. There were two complete responses (5%) and 12 partial responses (28%), producing an overall response rate of 33% [95% confidence interval (CI) 16% to 49%]. Thirteen patients (30%) had stable disease, whereas 16 (37%) had a progression. The median time to progression was 6 months and the median overall survival was 11 months. Twenty-five patients (64%, 95% CI 47% to 78%) experienced a clinical benefit response. Grade 3-4 WHO toxicities were: neutropenia in nine patients (21%); thrombocytopenia in four (9%); anaemia in five (12%); diarrhoea in four (9%); and asthenia in one (2%). CONCLUSIONS: A fixed dose-rate infusion of gemcitabine associated with UFT was well tolerated and showed promising activity in patients with locally advanced or metastatic carcinoma of the pancreas. This is an appropriate palliative treatment in this setting.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Deoxycytidine/analogs & derivatives , Maximum Tolerated Dose , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Adenocarcinoma/mortality , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biopsy, Needle , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Humans , Infusions, Intravenous , Male , Middle Aged , Neoplasm Invasiveness/pathology , Neoplasm Staging , Pancreatic Neoplasms/mortality , Probability , Statistics, Nonparametric , Survival Analysis , Tegafur/administration & dosage , Tegafur/adverse effects , Treatment Outcome , Uracil/administration & dosage , Uracil/adverse effects , Gemcitabine
19.
Emerg Infect Dis ; 8(10): 1044-7, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12396913

ABSTRACT

On October 12, 2001, two envelopes containing Bacillus anthracis spores passed through a sorting machine in a postal facility in Washington, D.C. When anthrax infection was identified in postal workers 9 days later, the facility was closed. To determine if exposure to airborne B. anthracis spores continued to occur, we performed air sampling around the contaminated sorter. One CFU of B. anthracis was isolated from 990 L of air sampled before the machine was activated. Six CFUs were isolated during machine activation and processing of clean dummy mail. These data indicate that an employee working near this machine might inhale approximately 30 B. anthracis-containing particles during an 8-h work shift. What risk this may have represented to postal workers is not known, but this estimate is approximately 20-fold less than a previous estimate of sub-5 micro m B. anthracis-containing particles routinely inhaled by asymptomatic, unvaccinated workers in a goat-hair mill.


Subject(s)
Air Microbiology , Anthrax/transmission , Bacillus anthracis/isolation & purification , Bioterrorism , Equipment Contamination , Occupational Exposure , Postal Service , Aerosols , Anthrax/microbiology , Colony Count, Microbial , Filtration/instrumentation , Humans , Risk Factors , Spores, Bacterial/isolation & purification , Workplace
SELECTION OF CITATIONS
SEARCH DETAIL
...